echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Ampere Bio's Philadelphia laboratory is operational.

    Ampere Bio's Philadelphia laboratory is operational.

    • Last Update: 2020-09-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    READ MORE: Global, Amperco Bio, Cancer Screening, Antibody Testing San Jose, Ca., August 11, 2020 /AGENCY/ -- Ampco Biomedical Technology Co., Ltd. ("Ampco" or "We" or "Company") (NASDAQ: ANPC) today announced that it has started operating its new Philadelphia laboratory and has completed the installation of its renovation facilities and phase 1 equipment in July 2020.
    phase 1 device in the laboratory is a Roche diagnostic analyzer, Cobas e411, which has been approved for emergency use by the FDA's new coronary pneumonia antibody test.
    Ampereco plans to conduct cancer screening studies for cancer differentiation analysis techniques and to provide commercial new coronary pneumonia antibody testing using Roche Cobas e411 devices, which will be used once they have been identified and approved separately in accordance with FDA regulations.
    since the second quarter of 2020, Ampeco San Jose Laboratory has verified the detection of new coronary pneumonia antibodies on the Roche Diagnostic Analyzer Cobas e411 machine.
    verification is completed in the second half of 2020, we will complete all other regulatory approvals and will be commercially available.
    , chief executive officer of Ampereco, commented, "The start-up of our Philadelphia laboratory marks a new stage of development for Ampereco in the United States.
    Our important patent pool (which has so far received 19 U.S. patents), highly innovative cancer screening technologies (cancer differentiation analysis techniques) and their sample size (greater than 180,000 sample sizes), well-known healthcare partners, and our biomedical laboratories on the East and West coasts will make a significant contribution to our success in the United States.
    " About Ampco Biomedical Technology Co., Ltd. Amperco Biomedical Technology Co., Ltd. is a biotechnology company dedicated to early cancer screening and testing, as of June 30, 2020, the company has a total of 128 patents.
    two certified clinical laboratories in China and CLIA and CAP-accredited clinical laboratories in the United States.
    is available for a range of cancer screening and testing tests, including CDA (Cancer Differentiation Analysis), Biotechnology, Immunology and Genomics.
    in its latest market research report, Frost and Sullivan, as of May 2020, based on 41,700 clinical samples, Ampco ranks third in the world and first in China among companies providing next-generation early-stage cancer screening and testing technologies.
    clinical samples show that Ampereco's CDA technology and platform can detect the risk of more than 20 types of cancer.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.